Innate pharma to hold its annual general meeting of shareholders on june 28, 2013, in Marseille, France
Innate Pharma announces 1Q2013 revenue and cash in line with expectations
Innate Pharma presents new data for proprietary programs targeting TLR3 and KIR3DL2
Annual results for 2012: significant advance for four drug candidates and strong cash position
Innate Pharma reports increase in annual revenue for 2012
Full-year report on Innate Pharma’s liquidity contract with Gilbert Dupont
Innate Pharma announces its financial calendar for 2013 as well as its participation to upcoming investor conferences
Phase I clinical trial of IPH2102/BMS-986015 in combination with ipilimumab announced
First patient treated in the EffiKIR trial
Update on clinical trials with IPH2101 in Multiple Myeloma
